Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells

Figure 1

Cytotoxic effects of imatinib in the presence of HS-5 conditioned medium. (A) K562 cells were cultured at a concentration of 8 × 104/mL in the presence of varying concentrations of imatinib in the presence or absence of HS-5 conditioned medium for 72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (B) K562 cells were treated with 2 μM imatinib alone or in combination with either 1 μM TG101348 or 5 μM AG490 in the presence or absence of HS-5 conditioned medium for 72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (C) K562 cells were cultured with the indicated concentrations of TG101348 for 72 h. Viable cell numbers were calculated. Results are representative of three separate experiments. (D) K562 cells were treated with TG101348 for 24 h, and total extracts were examined by immunoblotting using anti-phospho ABL, ABL, phospho-STAT5, STAT5, and β-actin Abs. Blots were scanned and optical densities were determined using ImageJ software.

Back to article page